S&P 500   4,076.26 (-0.09%)
DOW   34,388.24 (-0.58%)
QQQ   293.60 (+0.08%)
AAPL   148.37 (+0.23%)
MSFT   254.79 (-0.14%)
META   120.11 (+1.70%)
GOOGL   101.18 (+0.19%)
AMZN   95.54 (-1.04%)
TSLA   194.88 (+0.09%)
NVDA   171.42 (+1.29%)
NIO   12.14 (-5.01%)
BABA   86.12 (-1.64%)
AMD   77.10 (-0.68%)
T   19.14 (-0.73%)
MU   55.22 (-4.22%)
CGC   3.81 (+5.25%)
F   14.06 (+1.15%)
GE   85.46 (-0.59%)
DIS   98.09 (+0.22%)
AMC   8.89 (+22.96%)
PYPL   78.56 (+0.19%)
PFE   50.85 (+1.44%)
NFLX   317.78 (+4.01%)
S&P 500   4,076.26 (-0.09%)
DOW   34,388.24 (-0.58%)
QQQ   293.60 (+0.08%)
AAPL   148.37 (+0.23%)
MSFT   254.79 (-0.14%)
META   120.11 (+1.70%)
GOOGL   101.18 (+0.19%)
AMZN   95.54 (-1.04%)
TSLA   194.88 (+0.09%)
NVDA   171.42 (+1.29%)
NIO   12.14 (-5.01%)
BABA   86.12 (-1.64%)
AMD   77.10 (-0.68%)
T   19.14 (-0.73%)
MU   55.22 (-4.22%)
CGC   3.81 (+5.25%)
F   14.06 (+1.15%)
GE   85.46 (-0.59%)
DIS   98.09 (+0.22%)
AMC   8.89 (+22.96%)
PYPL   78.56 (+0.19%)
PFE   50.85 (+1.44%)
NFLX   317.78 (+4.01%)
S&P 500   4,076.26 (-0.09%)
DOW   34,388.24 (-0.58%)
QQQ   293.60 (+0.08%)
AAPL   148.37 (+0.23%)
MSFT   254.79 (-0.14%)
META   120.11 (+1.70%)
GOOGL   101.18 (+0.19%)
AMZN   95.54 (-1.04%)
TSLA   194.88 (+0.09%)
NVDA   171.42 (+1.29%)
NIO   12.14 (-5.01%)
BABA   86.12 (-1.64%)
AMD   77.10 (-0.68%)
T   19.14 (-0.73%)
MU   55.22 (-4.22%)
CGC   3.81 (+5.25%)
F   14.06 (+1.15%)
GE   85.46 (-0.59%)
DIS   98.09 (+0.22%)
AMC   8.89 (+22.96%)
PYPL   78.56 (+0.19%)
PFE   50.85 (+1.44%)
NFLX   317.78 (+4.01%)
S&P 500   4,076.26 (-0.09%)
DOW   34,388.24 (-0.58%)
QQQ   293.60 (+0.08%)
AAPL   148.37 (+0.23%)
MSFT   254.79 (-0.14%)
META   120.11 (+1.70%)
GOOGL   101.18 (+0.19%)
AMZN   95.54 (-1.04%)
TSLA   194.88 (+0.09%)
NVDA   171.42 (+1.29%)
NIO   12.14 (-5.01%)
BABA   86.12 (-1.64%)
AMD   77.10 (-0.68%)
T   19.14 (-0.73%)
MU   55.22 (-4.22%)
CGC   3.81 (+5.25%)
F   14.06 (+1.15%)
GE   85.46 (-0.59%)
DIS   98.09 (+0.22%)
AMC   8.89 (+22.96%)
PYPL   78.56 (+0.19%)
PFE   50.85 (+1.44%)
NFLX   317.78 (+4.01%)
NASDAQ:CRBP

Corbus Pharmaceuticals - CRBP Stock Forecast, Price & News

$0.15
-0.04 (-21.85%)
(As of 12/1/2022 02:12 PM ET)
Add
Compare
Today's Range
$0.14
▼
$0.17
50-Day Range
$0.11
▼
$0.19
52-Week Range
$0.10
▼
$0.90
Volume
389,385 shs
Average Volume
1.95 million shs
Market Capitalization
$19.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Corbus Pharmaceuticals MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
3.71% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.65
Upright™ Environmental Score
News Sentiment
0.93mentions of Corbus Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.25) to ($0.31) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.89 out of 5 stars

Medical Sector

787th out of 1,047 stocks

Pharmaceutical Preparations Industry

385th out of 512 stocks

See Top Rated MarketRank™ Stocks Here
CRBP stock logo

About Corbus Pharmaceuticals (NASDAQ:CRBP) Stock

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Receive CRBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRBP Stock News Headlines

November 25, 2022 | americanbankingnews.com
Corbus Pharmaceuticals (NASDAQ:CRBP) Research Coverage Started at StockNews.com
November 10, 2022 | finance.yahoo.com
Corbus Presents Latest Preclinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
November 8, 2022 | finance.yahoo.com
Corbus Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
October 25, 2022 | msn.com
Why Qualtrics International Shares Are Trading Sharply Higher; Here Are 23 Stocks Moving Premarket
October 14, 2022 | finance.yahoo.com
Corbus Pharmaceuticals to Present Pre-Clinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
September 26, 2022 | finance.yahoo.com
Corbus Pharmaceuticals Appoints Anne Altmeyer, PhD to Board of Directors
September 22, 2022 | finance.yahoo.com
Corbus Presents First Pre-Clinical Data for CRB-913 at the European Association for the Study of Diabetes 2022 Annual Conference
September 12, 2022 | finance.yahoo.com
Corbus Pharmaceuticals to Present Virtually at the H.C. Wainwright 24th Annual Global Investment Conference
August 9, 2022 | finance.yahoo.com
Corbus Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 6, 2022 | finance.yahoo.com
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
May 10, 2022 | apnews.com
Corbus Pharmaceuticals: Q1 Earnings Snapshot
May 10, 2022 | seekingalpha.com
Corbus Pharmaceuticals GAAP EPS of -$0.08 beats by $0.01
May 10, 2022 | markets.businessinsider.com
Corbus Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
April 18, 2022 | msn.com
Marijuana Stock Movers For April 18, 2022
April 8, 2022 | finance.yahoo.com
Corbus Presents First Preclinical Data for CRB-601 at the American Association for Cancer Research (AACR) Annual Meeting
April 7, 2022 | marketwatch.com
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors
April 7, 2022 | msn.com
Citius (CTXR) Posts Top-Line Data From Pivotal Lymphoma Study
April 5, 2022 | msn.com
Cannabis Stock Gainers And Losers From April 5, 2022
April 4, 2022 | marketwatch.com
Corbus Pharmaceuticals Holdings Inc. stock falls Monday, underperforms market
March 11, 2022 | finance.yahoo.com
Corbus Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference
March 8, 2022 | benzinga.com
Corbus Pharmaceuticals: Q4 Earnings Insights
March 8, 2022 | finance.yahoo.com
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Updates
March 2, 2022 | finance.yahoo.com
Akari Therapeutics Appoints Rachelle Jacques as President and Chief Executive Officer
February 15, 2022 | benzinga.com
Clever Leaves Expands Deal With Cannatrek In Australia Via $3.6M Sales Agreement To Include THC Flower
February 2, 2022 | msn.com
Cannabis Stock Gainers And Losers From February 2, 2022
See More Headlines
Receive CRBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRBP Company Calendar

Last Earnings
11/12/2021
Today
12/01/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/14/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRBP
CUSIP
N/A
CIK
1595097
Web
www.corbuspharma.com
Phone
(617) 963-0100
Fax
617-663-6085
Employees
41
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.34)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-45,640,000.00
Net Margins
N/A
Pretax Margin
-36,209.27%
Return on Equity
-66.27%
Return on Assets
-40.89%

Debt

Debt-to-Equity Ratio
0.22
Current Ratio
3.86
Quick Ratio
3.86

Sales & Book Value

Annual Sales
$880,000.00
Price / Sales
21.64
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.33 per share
Price / Book
0.46

Miscellaneous

Outstanding Shares
125,280,000
Free Float
115,008,000
Market Cap
$19.04 million
Optionable
Optionable
Beta
1.82

Key Executives

  • Dr. Yuval Cohen Ph.D. (Age 47)
    CEO & Director
    Comp: $846.92k
  • Mr. Sean F. Moran CPA (Age 64)
    M.B.A., CPA, MBA, Chief Financial Officer
    Comp: $542k
  • Mr. Craig Stuart Millian M.B.A. (Age 53)
    Chief Operating Officer
    Comp: $542k
  • Dr. Rachael Brake Ph.D. (Age 50)
    Chief Scientific Officer
  • Ted Jenkins
    Sr. Director of Investor Relations & Corp. Communications
  • Ms. Lindsey Smith
    Head of Corp. Communications & Patient Advocacy
  • Ms. Christina Bertsch
    Head of HR
  • Scott Constantine
    Sr. Director & Head of Clinical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













CRBP Stock - Frequently Asked Questions

How have CRBP shares performed in 2022?

Corbus Pharmaceuticals' stock was trading at $0.6157 at the beginning of 2022. Since then, CRBP shares have decreased by 74.5% and is now trading at $0.1571.
View the best growth stocks for 2022 here.

When is Corbus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 14th 2023.
View our CRBP earnings forecast.

How were Corbus Pharmaceuticals' earnings last quarter?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) released its quarterly earnings results on Friday, November, 12th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.10. The biopharmaceutical company earned $0.10 million during the quarter, compared to analysts' expectations of $0.81 million.

What other stocks do shareholders of Corbus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and KushCo (KSHB).

What is Corbus Pharmaceuticals' stock symbol?

Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."

Who are Corbus Pharmaceuticals' major shareholders?

Corbus Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include ETF Managers Group LLC (3.76%), Vanguard Group Inc. (3.23%), Pinnacle Associates Ltd. (0.66%), Renaissance Technologies LLC (0.63%), ExodusPoint Capital Management LP (0.29%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Barbara White, Craig Stuart Millian, Robert Paul Discordia, Sean F Moran and Yuval Cohen.
View institutional ownership trends.

How do I buy shares of Corbus Pharmaceuticals?

Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Corbus Pharmaceuticals' stock price today?

One share of CRBP stock can currently be purchased for approximately $0.16.

How much money does Corbus Pharmaceuticals make?

Corbus Pharmaceuticals (NASDAQ:CRBP) has a market capitalization of $19.68 million and generates $880,000.00 in revenue each year. The biopharmaceutical company earns $-45,640,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis.

How can I contact Corbus Pharmaceuticals?

Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The official website for the company is www.corbuspharma.com. The biopharmaceutical company can be reached via phone at (617) 963-0100, via email at ir@corbuspharma.com, or via fax at 617-663-6085.

This page (NASDAQ:CRBP) was last updated on 12/1/2022 by MarketBeat.com Staff